Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the...

Descripción completa

Detalles Bibliográficos
Autores principales: Conchon, Monika, Freitas, Carla Maria Boquimpani de Moura, Rego, Maria Aparecida do Carmo, Braga Junior, José Wilson Ramos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Hematologia e Hemoterapia 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520638/
https://www.ncbi.nlm.nih.gov/pubmed/23284261
http://dx.doi.org/10.5581/1516-8484.20110034
Descripción
Sumario:Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.

Ejemplares similares